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The overexpression of epidermal growth factor receptor (EGFR) is closely associated with a poor outcome
in non-small cell lung cancer (NSCLC), and EGFR is an ideal biomarker for the targeted therapy of NSCLC.
Although patients with EGFR-activating mutations respond to EGFR tyrosine kinase inhibitors (EGFR-
TKIs), they eventually acquire resistance, which typically results from a secondary EGFR mutation or the
activation of other signaling pathways. Novel approaches to overcome or prevent EGFR-TKI resistance are
clinically important. In this study, we developed an EGFR-scFv-arginine nonamer peptide fusion protein,
s-9R, as an siRNA carrier. Here, we show that s-9R effectively and speciﬁcally delivers EGFR-siRNAs,
KRAS-siRNA and MET-siRNA into NSCLC cells and silences the expression of target genes. The sensi-
tivity of NSCLC cells to geﬁtinib was restored after treatment with the s-9R/siRNA complex, and the
apoptosis rates of the treated cells were signiﬁcantly higher than those of the control groups. Further-
more, the co-administration of s-9R/siRNA and geﬁtinib successfully suppressed the progression of
H1975 xenograft tumors and extended the life span of tumor-bearing nude mice. Collectively, the results
of this study provide not only a new scFv derivative for delivering siRNA into EGFR-overexpressing, TKI-
resistant NSCLC cells but also a novel method for overcoming TKI resistance.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epidermal growth factor receptor (EGFR) is overexpressed in
approximately 60% of non-small cell lung cancer (NSCLC) cases. By
binding to ligands, EGFR regulates downstream signaling pathways,
most importantly the rat sarcoma (RAS) and phosphoinositide 3-
kinase (PI3K) pathways, and it plays an important role in tumor
cell proliferation, survival, migration and metastasis [1]. Tyrosineng), ruizhang@fmmu.edu.cn
Ltd. This is an open access article ukinase inhibitors (TKIs), particularly reversible inhibitors such as
erlotinib and geﬁtinib, are widely used in NSCLC patients harboring
EGFR-activating mutantions. However, patients who initially
responded to EGFR-TKI treatment, eventually developed resistance
to reversible EGFR-TKIs, which may be due to secondary EGFR
mutations or other resistance mechanisms [2]. The T790M point
mutation in exon 20 of EGFR, which increased the afﬁnity for ATP
and blocks the binding of TKIs to EGFR, is responsible for 50% of all
resistance to reversible TKIs [3]. In addition, Kirsten rat sarcoma
viral oncogene (KRAS) gene mutations, which result in the
stimulus-independent activation of KRAS and downstream effec-
tors and are proposed to be responsible for the primary resistance
to reversible inhibitors, exist in approximately 15e30% of NSCLC
tumors [4]. Mesenchymal to epithelial transition factor (MET) gene
ampliﬁcation also leads to EGFR inhibitor resistance by driving thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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20% of the NSCLC patients who initially responded to reversible
inhibitors and approximately 7% of TKI-naïve patients [5]. Other
mechanisms, including the epithelial-mesenchymal trans-
formation (EMT), the conversion of NSCLC to SCLC, AXL upregula-
tion and crk-like protein (CRKL) ampliﬁcation, also play a role in the
development of TKIs resistance [6].
New generation inhibitors have been developed to overcome
T790M resistance by covalently binding with ATP. Unfortunately,
most irreversible inhibitors are associated with severe adverse ef-
fects and the emergence of novel resistant mutations in NSCLC cells
[7e9]. Other therapeutic strategies to overcome the EGFR-TKI
resistance caused by MET ampliﬁcation or KRAS-activating muta-
tions have also been tested in clinical trials, but most of these
strategies involve small-molecule inhibitors or anti-EGFR anti-
bodies, which produce severe off-target effects [10]. Furthermore,
the ability to modulate TKI resistance has been complicated by the
fact that NSCLC simultaneously exhibits multiple resistance
mechanisms.
Silencing gene expression by siRNA might be a potent tool for
cancer treatment. However, the lack of efﬁcient and speciﬁc de-
livery methodologies is the main obstacle for the clinical success of
siRNA-based cancer therapeutics [11]. Studies have shown that
antibody-mediated targeted delivery is an effective method for
delivering and internalizing siRNA into particular cells [12e15]. A
single chain antibody (scFv) composed of variable regions of VH
and VL chains connected in tandemvia a short linker is an ideal tool
for delivering therapeutic reagents because it lacks both the con-
stant regions and the Fc domains, making it much smaller than the
intact antibody; thus, it has stronger penetrating capability and
lower immunogenicity [16]. However, successful delivery systems
also require efﬁcient vehicles to carry therapeutic agents. Arginine-
rich cell-penetrating peptides can bind and transduce nucleic acids,
such as DNA and siRNA, both in vitro and in vivo through electro-
static interactions. The 9R motif, a typical cell-penetrating peptide,
is more efﬁcient for cellular uptake than other oligomers containing
fewer arginine residues or other cationic amino acids such as his-
tidine, lysine or ornithine [17].
Given that lung cancer is the most common cancer and the
leading cause of cancer mortality worldwide [18], in the present
study, we attempted to overcome EGFR-TKI resistance in EGFR-
positive NSCLC cells by knocking down the expression of EGFR,
MET and KRAS using the powerful scFv-based delivery system
described above. We generated a single-chain EGFR antibody (scFv,
abbreviated as “s”), and fused it to a nine-mer arginine (9R) peptide
(s-9R). Our data show that s-9R efﬁciently delivers siRNA into
EGFR-overexpressing lung cancer cells, and our strategy potentiates
the effect of geﬁtinib on human NSCLC lines bearing TKI-resistant
mutations both in vitro and in vivo.
2. Materials and methods
2.1. Plasmid construction and protein puriﬁcation
The genes encoding scFv and s-9R were designed based on the
amino acid sequences of nimotuzumab. A linker (Gly4Ser3) was
connected to the VH and VL chains, and the nine-mer arginine-
encoding sequence was included in the 30scFv sequence to obtain
the s-9R fusion gene. To track the scFvs, we also included a 6  His-
encoding sequence in the 30scFv sequence, which was synthesized
by Augct Co. (Beijing, China). For bacterial expression, the scFv and
s-9R sequences were isolated as a BamHI/XhoI fragment from the T
vector and inserted into a BamHI/XhoI-digested plasmid, pGEX-4T-
1 (Novagen, Uppsala, Sweden). Single colonies of E. coli BL21 (DE3)
carrying the manufactured plasmid pGEX-4T-1-scFv for theexpression of the EGFR-speciﬁc scFv protein were grown overnight
at 37 C in 2  YT medium supplemented with 100 mg/ml ampi-
cillin. The cultures were then diluted 100-fold in the same medium
and incubated at 37 C until they reached an OD600 of 0.4e0.6. The
cultures were then induced with 0.1 mM isopropyl-1-thio-b-gal-
actopyranoside (IPTG) at 30 C for 5 h. The cells were harvested via
centrifugation (5000 g, 4 C, 15 min), washed in ice-cold phos-
phate-buffered saline (PBS), and then resuspended in binding
buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM
KH2PO4, pH 7.4). The soluble cell lysates were centrifuged at
12,000 g for 20 min after 30 min of sonication. Following the
manufacturer's instructions, the supernatant was then applied to a
glutathione S-transferase (GST)-afﬁnity column (GE Healthcare,
Uppsala, Sweden). The fusion proteins were eluted from the GST-
afﬁnity column using 10 mM reduced glutathione dissolved in
50mM TriseHCl (pH 8.0) at room temperature. The puriﬁed sample
was dialyzed against PBS (pH 8.0) for 24 h at 4 C and then incu-
bated with 25-fold diluted thrombin (Novagen, Darmstadt, Ger-
many) at room temperature for 8 h. Finally, the solutions were
ﬁltered in a GST afﬁnity column to remove the GST tag. The con-
centrations of the resultant fusion proteins were determined using
a bicinchoninic acid assay (Pierce, Rockford, IL, USA), and speciﬁc
proteins were identiﬁed by immuno-blotting with an anti-6  His
mouse monoclonal antibody (Qiagen, Valencia, CA, USA).
Detailed information about other experimental procedures is
provided in the Supplementary Materials.
3. Results
3.1. Puriﬁcation of the EGFR-targeting scFv and s-9R
For our study, we constructed the EGFR-targeting scFv and s-9R
based on nimotuzumab by sequentially fusing the VH and VL chains
with a G4S linker and a 6  His.tag. s-9R was also equipped with a
nine-mer arginine tail to carry the siRNA (Fig. 1A). The sequences
encoding scFv and s-9Rwere cloned into the pGEX-4T-1prokaryotic
expression vector (Fig. 1B). Following incubation in the presence of
IPTG, transformed E. coli cells expressed the recombinant single-
chain antibodies fused to the GST tag. The resulting fusion pro-
teins were cleaved by thrombin at room temperature and puriﬁed
using GST-afﬁnity chromatography. We detected the fusion pro-
teins using SDS-PAGE and observed that the molecular weight of
scFv and s-9R was approximately 26 kDa, which is consistent with
the expected size. The purity of the fusion proteins was greater than
90% based on optical density analyses of the bands (Fig. 1C), and the
scFvs fused with 6  His peptide tag were further identiﬁed by
Western blotting using an anti-6  His.tag antibody (Fig. 1D).
3.2. The scFv and s-9R fusion proteins retain the EGFR-binding
ability and are internalized by EGFR-positive lung cancer cells
The binding ability of the scFv and s-9R to EGFR was conﬁrmed
using ELISA. As shown in Fig. 2A, the two fusion proteins retained
antibody afﬁnity for recombinant EGFR proteins but not the nega-
tive control protein BSA. The rate of antibody-immobilized
coupling gradually decreased as the concentrations of scFv and s-
9R decreased. For the ﬂow cytometry (FCM) assay, the lung cancer
cell lines were incubated with the fusion proteins, and the cellular
ﬂuorescence intensity was monitored. The FITC ﬂuorescence of
EGFR-positive A549, H1975 and H1993 cells exceeded that of EGFR-
negative H69 cells, which showed only background ﬂuorescence,
by 15-fold; the proportion of FITC-stained H69 cells did not exceed
5% on average (Fig. 2B). The shift in the cellular FITC peak in the
FCM assay represents an increase in the number of ﬂuorescence-
positive cells. This shift was not observed in the EGFR-deﬁcient
Fig. 1. Expression and puriﬁcation of s-9R and scFv. (A) Schematic diagram of s-9R and scFv. (B) Restriction enzyme digestion result of the s-9R and scFv expression plasmids in
pGEX4T-1. (C) SDS-PAGE of expressed and puriﬁed s-9R and scFv fusion proteins. (D) Identiﬁcation of puriﬁed s-9R and scFv fusion proteins by Western blot.
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bodies. However, the peak occurred in EGFR-positive A549, H1975
and H1993 cells incubated with scFv or with s-9R (Fig. 2C). To
conﬁrm that the fusion proteins can bind to and be internalized by
EGFR-positive cells, we incubated NSCLC cells with scFv or s-9R for
6 h before immunoﬂuorescence staining and used Cy3-conjugated
secondary antibody to locate both of single chain antibodies in
target cells. The A549, H1975 and H1993 cells incubated with the
fusion proteins showed red ﬂuorescence from the Cy3 dye. The
signal was observed on the cell membranes, dispersed in the
cytoplasm and even in the nuclei of the EGFR-positive cells. Fluo-
rescence signals were not detected in the H69 cells in any of the
groups. To rule out the possibility of nonspeciﬁc effects, the cells
were also transfected with EGFR-siRNA using Lipofectamine2000
48 h before the fusion proteins were added. The pre-transfection
almost completely abrogated the cellular uptake of the fusion
proteins (Fig. 2D). Therefore, the fusion proteins speciﬁcally target
EGFR-positive lung cancer cells.
3.3. The s-9R fusion protein can target and deliver siRNA into EGFR-
positive lung cancer cells
The amount of the s-9R fusion protein mixed with the nonspe-
ciﬁc nucleotide fragments negatively correlated with the migration
rate of the nucleotide fragments. In contrast, nucleotide fragments
mixedwith scFvor BSA showedno signiﬁcant change in gelmobility
(Fig. 3A). To determine the molar ratio between the s-9R and siRNA
in additional experiments, a colorimetric binding assay wasperformed. Speciﬁcally, each s-9R molecule was bound to approxi-
mately three FAM-labeled siRNAs (FAM-siRNAs) (Fig. S1). To deter-
mine whether the s-9R fusion protein could speciﬁcally deliver
siRNA into EGFR-positive cells, FAM-siRNA was added to A549,
H1975, H1993 and H69 cells in combination with scFv, s-9R or BSA
before the FCM analysis. The EGFR-positive cells were unable to
internalize the FAM-siRNA that was mixed with scFv or BSA.
Moreover, the EGFR-positive cells effectively internalized the FAM-
siRNA thatwasmixedwith the s-9R fusionprotein, but theH69 cells
did not (Fig. 3B and C). Lipofectamine2000-mediated transfection
served as a positive control for siRNA delivery. We next evaluated
the speciﬁcity of siRNA delivery with LSCM. FAM-siRNA was pre-
mixed with s-9R, scFv or BSA for 30 min and then added to the
cell culture medium. The cells were then incubated for 6 h Lip-
ofectamine2000-mediated transfection of FAM-siRNA was used as a
positive control. As shown in Fig. 3D, the greenﬂuorescence of FAM-
siRNA, which was mixed with s-9R and Lipofectamine2000, was
located on the surface of the EGFR-positive lung cancer cells and
scattered throughout the entire cytoplasm, whereas pre-incubation
with scFvand the irrelative protein BSAdidnot result in cellular FAM
ﬂuorescence. None of the H69 cells ﬂuoresced when treated with s-
9R/FAM-siRNA or scFv/FAM-siRNA, although the FAM-siRNA that
was transfected with Lipofectamine2000 could be detected.
3.4. Speciﬁc siRNAs delivered by s-9R inhibited KRAS, EGFR and
MET gene expression
In this study, we used three NSCLC cell lines that harbored
Fig. 2. Binding and internalization of the fusion proteins. (A) Detection of the EGFR-binding ability of s-9R and scFv by ELISA. (B and C) The binding of the fusion proteins to EGFR-
positive NSCLC cells was assessed by an FCM assay. Lung cancer cells were incubated with PBS (red), scFv (blue) or s-9R (green) at 37 C for 6 h. (D) Recognition of EGFR and
internalization of the fusion proteins visualized by LSCM (EGFRsi: EGFR-siRNA). Lung cancer cells were incubated with the fusion proteins or BSA for 6 h before immunoﬂuorescence
staining (Red: Cy3; Blue: DAPI). Scale bar ¼ 20 mm. A result representative of 3 independent experiments is shown, **p < 0.01.
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A549 cells carrying wild-type EGFR and the KRAS mutation [19],
H1975 cells expressing L858R/T790M EGFR [20], and H1993 cells
harboring a MET ampliﬁcation [21]. A549, H1975 and H1993 cells
were treated with complexes of scFv, s-9R or BSA and the indicated
siRNA (100 nM). We evaluated the KRAS, EGFR and MET gene
expression using RT-qPCR and Western blot analysis. The resultsshowed that the mRNA expression levels of KRAS, EGFR and MET
were substantially lower in the s-9R/siRNA treatedgroups than in the
BSA/siRNA or scFv/siRNA group (Fig. 4A). Down-regulated gene
expressionwas also conﬁrmedwith aWestern blot of cells incubated
for 3 dayswith the above treatments. As shown in Fig. 4B, similarly to
the observations at the mRNA level, the siRNA delivered by s-9R
efﬁciently inhibited the KRAS, EGFR and MET protein expression.
Fig. 3. siRNA can be speciﬁcally delivered into EGFR-positive NSCLC cells by the s-9R fusion protein. (A) Nucleotide binding ability of the s-9R and scFv fusion proteins determined
by a gel mobility-shift assay. (B and C) FAMesiRNA (FAMsi) was pre-mixed with scFv (blue), s-9R (green), BSA (red) or Lipofectamine2000 (black) before being added to the medium
of lung cancer cells. FAM ﬂuorescence was detected by FCM analysis 6 h later. (D) Speciﬁc delivery of FAM-siRNA (green) visualized by LSCM. Lung cancer cells were incubated with
s-9R/FAM-siRNA, scFv/FAM-siRNA or BSA/FAM-siRNA for 6 h. Cells transfected with FAM-siRNA by Lipofectamine2000 served as the positive control. To knockdown EGFR expression,
we transfected cells with EGFR-siRNA using Lipofectamine2000 (Lipo) 48 h before incubation. Cells were counterstained using DAPI (blue) dye. Scale bars ¼ 20 mm. A result
representative of 3 independent experiments is shown, **p < 0.01.
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positive TKI-resistant NSCLC cells in vitro
The A549, H1975 and H1993 cells were treated with complexes
of the fusion proteins or BSA and the indicated siRNA; geﬁtinib
(100 nM) was also added to the cell culture medium 72 h before the
cell proliferationwasmeasured using anMTTassay. Comparedwith
BSA/siRNA or scFv/siRNA, the siRNA delivered by s-9R signiﬁcantly
inhibited the EGFR-positive NSCLC cell proliferation and restored
the sensitivity of the three lung cancer cells to geﬁtinib. Compared
with treatment with either agent alone, the combination of s-9R/siRNA and geﬁtinib synergistically potentiated apoptosis (Fig. 4C).
The proliferation ratios of the A549, H1975 and H1993 cell lines
that were treated with s-9R/siRNA plus geﬁtinib were in the same
range: 70.74 ± 7.67%, 71.72 ± 1.23% and 68.61 ± 5.64%, respectively.
However, the proliferation of the cells treated with BSA/siRNA or
scFv/siRNA plus geﬁtinib was not markedly inhibited, conﬁrming
that the reduction in cell growth was mediated by the combination
of the EGFR-TKI with a speciﬁc siRNA that can be transferred to cells
via either s-9R or Lipofectamine2000. Cells undergoing apoptosis
were also analyzed using the FCM assay. As shown in Fig. 4D, the
apoptosis rate was signiﬁcantly increased in the three EGFR-
Fig. 4. siRNA delivered by s-9R reduced the targeted gene expression in EGFR-positive cells and inhibited cell proliferation. (AeB) RT-qPCR for KRAS, EGFR and MET mRNA and
immunoblot analysis of KRAS, EGFR and MET proteins in A549, H1975 and H1993 cells. (C) MTT assays of A549, H1975 and H1993 cells treated as indicated. *p < 0.05, **p < 0.01. (D)
Apoptosis analysis of EGFR-positive cells treated as indicated assessed by FCM.
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the apoptosis rate of cells treated with scFv/siRNA alone or in
combination with geﬁtinib did not markedly change. Therefore, s-
9R/siRNA restored the sensitivity of EGFR-positive NSCLC cells to
geﬁtinib by silencing the expression of resistance-related genes.3.6. s-9R-delivered, EGFR-speciﬁc siRNA suppresses tumor growth
in vivo
To visualize the EGFR tumor targeting, the fusion proteins were
conjugated to DyLight 800 dye for nudemouse studies. The DyLight
Y. Lu et al. / Biomaterials 76 (2016) 196e207202800 conjugates showed a distinct absorbance peak at 780 nm
(Fig. S2). The distribution of the intravenously injected, DyLight
800-labeled scFv and s-9R was examined in lung cancer cells
implanted nude mice using a whole-body near-infrared ﬂuores-
cence living imaging (FLI) system. After the xenografts grew locally
around the injection site, we injected DyLight 800-labeled scFv, s-
9R or BSA via the tail vein. As demonstrated in Fig. 5A and B, three
dye-labeled proteins diffused rapidly throughout the whole bodies
of H1975 tumor-bearing mice via the venous system in 1 h. Eight
hours later, the fusion proteins were gradually cleared from the
normal tissues and were enriched in the tumor tissues until 48 h. In
contrast, BSA was cleared from the body 8 h post-injection, and
ﬂuorescence was detected mainly in the kidneys but not in the
tumor tissues. During the whole observation period, ﬂuorescence
of DyLight 800-conjugated proteins did not accumulate in the H69Fig. 5. In vivo distribution of scFv and s-9R in H1975 and H69 tumor-bearing mice. (A)
Whole-body images of the fusion protein distribution. Images obtained at indicated
time intervals after injection. (B) Fluorescence images of tumor sections.tumor tissues. The distribution of the intravenously-injected pro-
tein/siRNA complexes was also evaluated inmodel nudemice using
FLI. We injected Cy5-siRNA (20-O-me modiﬁed) pre-mixed with
BSA, scFv or s-9R via the tail vein. We observed that the Cy5-siRNA
mixed with s-9R was intracorporeally distributed in the same
pattern as the single-chain antibody alone. As shown in Fig. 6A, the
venous system distributed ﬂuorescence throughout the entire body
in every group 1 h after injection in the H1975-tumor-bearingmice.
Eight hours later, the s-9R/Cy5-siRNA complexes were gradually
cleared from the normal tissues and were enriched in the tumor
tissues until 48 h. In contrast, the siRNAmixedwith BSA or scFvwas
mainly localized in the kidney until 48 h after the injection, pre-
sumably because these components were eliminated by the kidney.
Similarly, Cy5 ﬂuorescence did not accumulate in any of the H69
cell tumors during the entire observation period, and it rapidly
dissipated. A signiﬁcant ﬂuorescent signal was not detected in the
H1975-tumor-bearing mice receiving BSA/Cy5-siRNA or scFv/Cy5-
siRNA. Forty-eight hours after the injection, we harvested tumors
and organs to assess the distribution of the exclusively EGFR-
positive tumor. As demonstrated in Fig. 6B and Fig. S3, the ﬂuo-
rescence was concentrated in the H1975 tumors treated with s-9R/
Cy5-siRNA but was not detected in the H69 tumors, indicating that
s-9R targets EGFR. Weak signals were detected in the liver and
spleen, and the ﬂuorescence accumulation in the heart, muscle and
lung was negligible. Notably, a relatively strong ﬂuorescence signal
showed accumulation in the kidney of the H1975-tumor-bearing
mice receiving s-9R/Cy5-siRNA 48 h after injection. To conﬁrm the
intracorporeal distribution of s-9R/siRNA, we injected BSA, scFv or
s-9R/FAM-siRNA (20-O-me modiﬁed) complexes into the tail vein.
Forty-eight hours later, the frozen xenografts sections were pre-
pared and examined under an LSCM. As shown in Fig. 6C, green
ﬂuorescence was detected in the H1975 tumor sections treated
with the s-9R/FAM-siRNA complex, but not in the H1975 tumor
sections receiving BSA/FAM-siRNA or scFv/FAM-siRNA or in any of
the H69 tumor sections.
We next investigated the in vivo antitumor activity of the s-9R/
siRNA complex. The mice bearing H1975 tumors received intrave-
nous injections of s-9R or the scFv/EGFR-siRNA complex twice per
week for 6 weeks, whereas a PBS solution of BSA/EGFR-siRNA was
used as a negative control. In addition, geﬁtinib was intragastrically
administered to nude mice. As observed in the immunohisto-
chemistry (IHC) analysis of tumor sections from the s-9R/EGFR-
siRNA plus geﬁtinib group, the H1975 xenografts showed reduced
EGFR staining. Furthermore, the cell proliferation, as assessed
based on the proportion of Ki-67-positive cells, decreased from
>60% in the control groups to 17.67 ± 2.52% in the treated groups.
Signiﬁcantly enhanced apoptosis was also observed by assessing
the proportion of terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP nick end labeling (TUNEL)-positive cells, which
increased from approximately 2% in the control groups to
68.33 ± 4.16% in the treated groups. However, the same treatment
did not signiﬁcantly alter these parameters in the EGFR-deﬁcient
H69 xenografts (Fig. 7A and B). Compared to the control groups
that received scFv or BSA/EGFR-siRNA complexes plus geﬁtinib oral
gavage, the H1975 tumor growth was markedly suppressed by the
s-9R/EGFR-siRNA plus geﬁtinib treatment, and tumors were not
readily detected, as indicated by their negligible weight and size
(Fig. 8A and B). Two of seven mice treated with these combination
therapies did not develop measurable tumors. Moreover, a
KaplaneMeier survival analysis revealed that mice bearing H1975
xenografts and treated with s-9R/EGFR-siRNA plus geﬁtinib sur-
vived longer than the mice in the other groups, including the H69
xenograft-bearing mice treated with the same drug combination
(Fig. 8C). This ﬁnding further supports the potent effect of the
treatment with a targeted siRNA plus an oral TKI. Therefore, we
Fig. 6. In vivo targeted delivery of siRNA mediated by s-9R. (A) Whole-body images of the distribution of Cy5-siRNA, which was pre-mixed with the fusion proteins or BSA. Images
obtained at indicated time intervals after injection. (B) Fluorescence images of tumor sections. (C) Mice treated with protein/FAM-siRNA before necropsy. Fluorescence images of
tumor cryosections were taken by LSCM. Scale bar ¼ 20 mm.
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the s-9R/EGFR-siRNA plus geﬁtinib treatment was likely mediated
by the inhibition of tumor cell proliferation and the induction of
apoptosis due to selective EGFR gene knockdown.
3.7. Expression and clinico-pathological correlation of EGFR in
human NSCLC specimens
To assess the expression levels of EGFR and its effect on prog-
nosis, we screened 75 human NSCLC specimens and analyzed the
correlation between EGFR and clinico-pathological parameters as
well as follow-up information. As shown in Table 1, 44 cases of
EGFR-positive NSCLC accounting for 58.66% of the available NSCLC
cases were examined, including 37 adenocarcinomas, 32 squamous
cell carcinomas and 6 large cell lung cancers. The median survival
time of these patients was 16.3 months. Twenty-six patients died
within 6 months (34.7%), and the specimens from these patients
were all EGFR-positive; 18 patients died within 1 year of the
diagnosis (24%) and 15 of these specimens were EGFR-positive
(83.3%); 31 survived more than 1 year (41.3%), and only 3 samples
from these patients were EGFR-positive (9.7%). More importantly,
positive EGFR expression in NSCLC signiﬁcantly correlated with
lymph node metastasis (p ¼ 0.005) and distant metastasis(p¼ 0.013), which suggests that EGFR-positive patients may beneﬁt
from an adjuvant immuno-drug strategy.
4. Discussion
Patients with NSCLC who initially respond to reversible EGFR
inhibitors almost invariably develop resistance to EGFR TKIs and
relapse after several months. This problem is thought to be due to
the secondary mutation of EGFR or a kinase-mediated bypass
mechanism associated with the activation of downstream signaling
pathways of EGFR [6]. Several new agents, so-called secondary
generation inhibitors, have been developed as an irreversible pan-
EGF receptor TKI to overcome EGFR-TKI resistance and prolong
responses. However, the toxicities associated with irreversible in-
hibition of wild-type EGFR were so severe as to lead to dose re-
ductions or treatment termination [22]. Third-generation inhibitors
that spared wild-type EGFR were developed and have shown
promising clinical activity [23]. However, the co-occurrence of
multiple resistance mechanisms, such as EGFR T790M mutation
and MET ampliﬁcation, within a given tumor sample or among
different sites of disease limits the therapeutic efﬁcacy of mutant-
speciﬁc EGFR inhibitors [10]. Moreover, mechanisms that lead to
direct resistance against these novel inhibitors in NSCLC cells have
Fig. 7. Intravenous injection of s-9R/EGFR-siRNA reduced EGFR expression and induced apoptosis in EGFR-positive tumors by restoring geﬁtinib sensitivity. (A) Nude mice bearing
H1975 or H69 xenografts were treated with protein/siRNA and geﬁtinib. Representative microscopy images (200) of tumor sections stained for EGFR, Ki67 and TUNEL are shown.
Scale bar ¼ 50 mm. (B) Percentages of TUNEL- or Ki67-positive cells from six randomly selected ﬁelds of parafﬁn-embedded tumor sections. **p < 0.01.
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overcoming reversible EGFR-TKI resistance involve the simulta-
neous blocking of parallel signaling pathways. Mutant KRAS protein
is constitutively activated, which leads to stimulus-independent,
persistent activation of downstream effectors and consequently
resistance to EGFR inhibitors [25]. However, not all cancer cells that
harbor RAS mutations depend on mutant RAS to survive; inhibiting
KRAS by itself might be insufﬁcient to terminate cancer growth and
progression [26]. More importantly, inhibitors targeting KRAS
signaling block KRAS and NRAS geranylgeranylation, have severe
toxicity [27]. MET can cross-talk with ERBB3, a member of the EGFR
family, and consequently stimulate the ERBB3-dependent activa-
tion of PI3K/AKT signaling in an EGFR-independent manner [28].
Inhibitors of the MET protein have been tested in clinical trials, but
no compelling evidence of a clinical beneﬁt was obtained in NSCLC
patients whose initial treatment with TKIs failed [29].
Small RNAs, including EGFR-speciﬁc siRNAs and multi-target
microRNAs, have been shown to strongly synergize with EGFR-
TKIs to inhibit the proliferation of lung cancer cells [30,31]. The
success of siRNA therapy depends on the optimization of site-
speciﬁc transportation, serum stability and cellular uptake, which
has hindered its application in the clinic. Recently, Jiang, et al. re-
ported an anti-HER2 single-chain antibody (e23sFv-9R) that can
deliver CXCR4-siRNA to breast cancer cells to exert anti-tumor ef-
fects [32]. In the present study, we designed and produced two new
EGFR-speciﬁc scFvs in E. coli using the amino acid sequence of
nimotuzumab, which is a well-established anti-EGFR mAb pos-
sessing potent antitumor immuno-activity, and is beinginvestigated in several clinical trials for the treatment of malig-
nancies [33e35]. A previous study used nimotuzumab conjugated
to isotopes to detect EGFR-positive breast cancer, and showed that
its conjugates can bind to EGFR and can be internalized and
transported to the cytoplasm and nuclei of EGFR-positive cancer
cells [36]. Considering the speciﬁc binding and internalization of
nimotuzumab, we speculated that nimotuzumab derivatives might
deliver siRNA into the cytoplasm of target cells and speciﬁcally
silence target genes. In addition, considering the molecular weight
and inﬂuence on the protein spatial structure, we selected 9R
rather than protamine as the siRNA carrier. Data showed that 9R did
not affect the selectivity of the scFv for EGFR-positive NSCLC cells.
Additionally, to increase the serum stability and reduce off-target
activity, we modiﬁed the seed region of the siRNA via 20-O-
methylation, which did not compromise the silencing ability of
siRNA [12]. Generally, our data showed that the new s-9R fusion
protein can selectively deliver siRNA into EGFR-TKI-resistant NSCLC
cells and efﬁciently silence target gene expression. When co-
administered with geﬁtinib, the siRNA delivered by s-9R effec-
tively inhibited the proliferation of resistant NSCLC cells, induced
apoptosis and enhanced the xenograft tumor response to geﬁtinib.
The EGFR-TKI treatment ampliﬁes the suppression of tumor cell
growth and the induction of apoptosis by siRNA. In vitro, neither the
EGFR-siRNA that was transfected using Lipofectamine2000 nor that
delivered using s-9R as a monotherapy efﬁciently suppressed the
viability of H1975 cells; these ﬁndings are slightly inconsistent with
previous data [30]. These differences might be the result of the
lower concentration of siRNA used in our study and the ability of
Fig. 8. Inhibited tumor growth and prolonged life span of mice bearing H1975 xenografts. (A) Tumor volumes are presented as growth curves, and (B) digital pictures of the tumors
were recorded in each group; the tumors were weighed after sacriﬁce. Data are expressed as the means ± S.D. for each group. **p < 0.01. (C) KaplaneMeier survival curve.
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H1975 cells, which carries a T790M mutation plus an L858R mu-
tation in exon 21, is considered a less potent driver of cell growth
and survival than the EGFR in TKI-resistant cell lines that carry an
exon 19 deletion. Interestingly, the rates of apoptosis induced by
the s-9R-mediated siRNA delivery or Lipofectamine2000-mediated
siRNA transfection did not differ in the presence of geﬁtinib;
furthermore, the latter strategy more efﬁciently silenced gene
expression than did the former. We suppose that the antigen-
blocking capacity of scFv may play an important part in promot-
ing apoptosis. Cancer cells are targeted by three mechanisms: the
scFv moiety prevents the receptor dimerization, the receptor wasthen physically eliminated by EGFR-targeted siRNA, and geﬁtinib
inhibits the enzymatic activity of EGFR signaling pathways.
KRAS and EGFR in human lung tumors activate common
signaling pathways to support tumorigenesis. A previous report
showed that KRAS knockdown by a speciﬁc siRNA restored TKI
sensitivity in KRAS-activated A549 cells [37]. Mutant KRAS knock-
down increased the sensitivity of NSCLCs with wild-type EGFR to
geﬁtinib by necessitating the need for signaling via the ligand-
dependent activation and phosphorylation of EGFR and thus
increasing survival [38]. In our study, KRAS ablation did not
signiﬁcantly diminish the viability of A549 cells, which is consistent
with the ﬁndings of other studies, whereas the combination
Table 1
Correlation between clinico-pathological parameters and EGFR expression.
Feature N EGFR positive (%) P value
Age (Year) 0.483
<60 36 27(75)
60 39 17(43.6)
Sex 0.979
Male 51 29(56.9)
Female 24 15(62.5)
Pathologic type 0.089
Adenocarcinma 37 25 (67.6)
Squamous cell carcinoma 32 17(53.1)
Others 6 2(33.3)
Lymph node metastasis 0.005
No 16 4(25)
Yes 59 40(67.8)
Distant metastasis 0.013
No 30 9(30)
Yes 45 35(77.8)
Survival time (months) 0.000
<6 26 26(100)
>6, <12 18 15(83.3)
12 31 3(9.7)
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TKIs [39]. However, constitutive MET phosphorylation is insufﬁ-
cient to induce EGFR-TKI resistance in NSCLC cells, and further
activation by HGF or MET ampliﬁcation might be necessary [40]. A
previous study showed that MET downregulation can sensitize
EGFR-TKI-resistant lung cancer cells to geﬁtinib [41]. In the present
study, we used s-9R to deliverMET-speciﬁc siRNA intoTKI-resistant
H1993 cells to speciﬁcally knockdownMETexpression. By silencing
MET gene expression, we reduced the amount of MET on the cell
surface to a level far below the threshold level for TKI resistance by
preventing the activation of downstream PI3K/Akt-pathway
effectors.
Drug combination strategies, including rational combinations of
target therapy, chemotherapy and immunotherapy that block
various targets, can augment the potency of EGFR signaling inhi-
bition and suppress TKI-resistant cancer cells. Nevertheless,
improving long-term survival outcomes without ampliﬁed toxic-
ities is a major goal for combination therapies that are designed to
circumvent resistance. Taking advantage of the ability of s-9R to
deliver siRNAs directly to cancer cells in vivo, we demonstrated that
the combination of immunotherapy and small molecular inhibitors
more effectively inhibited the tumor in the model system than did
the control treatments. Our results provide preclinical support for
the therapeutic potential of s-9R/siRNA, which has great potential
to restore the sensitivity of EGFR-TKI-resistant NSCLC cells and to
avoid non-speciﬁc side-effects.
scFv/siRNA complexes hold great promise as therapeutic agents
for NSCLC through the application of RNAi to oncogene expression.
However, some problems still must be solved before our strategy
can be applied clinically. First, because the siRNA sequences in this
study target both the mutated and wild-type EGFR and KRAS
mRNA, future work is needed to investigate the possibility of a
speciﬁc knockdown of the mutated EGFR and KRAS by designing
mutant-speciﬁc siRNAs. Second, the antibody must be modiﬁed
further to optimize the loading capacity of the nucleic acids and the
binding stability between scFv and siRNA by fusing themwith other
positively charged peptides or adopting artiﬁcial polymers. Third,
the release of siRNA from endosomes should be accelerated by
fusion with motifs that exert endosomolytic activity. Finally,
although the antibody fusion protein complexed with siRNA does
not induce interferon or activate other nonspeciﬁc inﬂammatory
responses when administered in vivo [12,32,42], we did not observeany obvious toxicity or inﬂammatory inﬁltrate in our tumor-
bearing mouse model. This result needs to be investigated more
carefully and veriﬁed in a future study.
Our strategy may beneﬁt NSCLC patients harboring wild-type
EGFR, who account for approximately 60% of East Asians and 85%
of Caucasians, who are now excluded from EGFR-TKI treatment
[28]. Patients harboring more than one resistant mutation in a
single tumor site may also beneﬁt from our method because the s-
9R could be used to deliver any mixture of siRNAs that target
different genes associated with EGFR-TKI resistance. Furthermore,
EGFR is overexpressed in a variety of epithelial tumors [43]. Small
molecular inhibitors, mostly RTK inhibitors, have been widely used
in clinics to treat these tumors, but their effectiveness has been
hampered by the emergence of drug resistance. Theoretically, our
strategy can be easily adapted to sensitize these EGFR-positive tu-
mor cells by sensibly silencing target genes associated with drug
resistance. Last but not least, the antibody-mediated EGFR-speciﬁc
delivery systems might be useful for the future development of
multifunctional vesicles for simultaneous target imaging, drug
delivery and real-time monitoring of the therapeutic effect to treat
EGFR-overexpressed cancers and other diseases by conjugation
with magnetic nanoparticles.
5. Conclusions
The strategy of using an scFv antibody to deliver siRNA might be
useful for overcoming TKI resistance in EGFR-overexpressing NSCLC
patients whose therapy fails due to intrinsic or acquired resistance.
In the present work, we generated two EGFR-speciﬁc scFvs and
conﬁrmed their binding and internalization capacity. We efﬁciently
silenced the expression of targeted genes by utilizing s-9R, which is
internalized by NSCLC cell lines, as an siRNA carrier. Co-treatment
with s-9R/siRNAs and geﬁtinib successfully induced apoptosis in
TKI-resistant NSCLC cells in vitro and suppressed xenograft tumor
progression in vivo. The synthesis and application of new small-
molecule inhibitors will likely result in novel causes of TKI resis-
tance. Thus, we could restore the TKI-resistant cancer cell sensi-
tivity by selecting suitable targets for knockdown. This scFv
antibody-mediated siRNA delivery system and the combination
strategy can increase the possibility of using siRNA therapeutically
to overcome EGFR-TKI resistance in clinical applications.
Acknowledgments
TheNational Natural Science Foundation of China (No.81172222)
and the Social Development Project Foundation of Shaanxi Province
(No.2011K15-06-02) are gratefully acknowledged.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.biomaterials.2015.10.036.
References
[1] N.E. Hynes, H.A. Lane, ERBB receptors and cancer: the complexity of targeted
inhibitors, Nat. Rev. Cancer 5 (2005) 341e354.
[2] G. Giaccone, Y. Wang, Strategies for overcoming resistance to EGFR family
tyrosine kinase inhibitors, Cancer Treat. Rev. 37 (2011) 456e464.
[3] C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, et al.,
The T790M mutation in EGFR kinase causes drug resistance by increasing the
afﬁnity for ATP, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2070e2075.
[4] William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan,
Marc Ladanyi, et al., KRAS mutations and primary resistance of lung adeno-
carcinomas to geﬁtinib or erlotinib, PLoS Med. 2 (2005) e17.
[5] J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, et al.,
MET ampliﬁcation leads to geﬁtinib resistance in lung cancer by activating
ERBB3 signaling, Science 316 (2007) 1039e1043.
Y. Lu et al. / Biomaterials 76 (2016) 196e207 207[6] C. Rolfo, E. Giovannetti, D.S. Hong, T. Bivona, L.E. Raez, G. Bronte, et al., Novel
therapeutic strategies for patients with NSCLC that do not respond to treat-
ment with EGFR inhibitors, Cancer Treat. Rev. 40 (2014) 990e1004.
[7] Lorenza Landi, F. Cappuzzo, Irreversible EGFR-TKIs: dreaming perfection,
Transl. Lung Cancer Res. 2 (2013) 40e49.
[8] D. Ercan, K. Zejnullahu, K. Yonesaka, Y. Xiao, M. Capelletti, A. Rogers, et al.,
Ampliﬁcation of EGFR T790M causes resistance to an irreversible EGFR in-
hibitor, Oncogene 29 (2010) 2346e2356.
[9] K.S. Thress, C.P. Paweletz, E. Felip, B.C. Cho, D. Stetson, B. Dougherty, et al.,
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small
cell lung cancer harboring EGFR T790M, Nat. Med. 21 (2015) 560e562.
[10] H.A. Yu, G.J. Riely, C.M. Lovly, Therapeutic strategies utilized in the setting of
acquired resistance to EGFR tyrosine kinase inhibitors, Clin. Cancer Res. 20
(2014) 5898e5907.
[11] S.Y. Wu, G. Lopez-Berestein, G.A. Calin, A.K. Sood, RNAi therapies: drugging
the undruggable, Sci. Transl. Med. 6 (2014) 240ps7.
[12] Y.D. Yao, T.M. Sun, S.Y. Huang, S. Dou, L. Lin, J.N. Chen, et al., Targeted delivery
of PLK1-siRNA by ScFv suppresses Her2þ breast cancer growth and metas-
tasis, Sci. Transl. Med. 4 (2012) 130ra48.
[13] W.-H. Wen, J.-Y. Liu, W.-J. Qin, J. Zhao, T. Wang, L.-T. Jia, et al., Targeted in-
hibition of HBV gene expression by single-chain antibody mediated small
interfering RNA delivery, Hepatology 46 (2007) 84e94.
[14] F. Wang, H.R. Bai, J. Wang, Y.Z. Bai, C.W. Dou, Glioma growth inhibition in vitro
and in vivo by single chain variable fragments of the transferrin receptor
conjugated to survivin small interfering RNA, J. Int. Med. Res. 39 (2011)
1701e1712.
[15] P. Kumar, H.S. Ban, S.S. Kim, H. Wu, T. Pearson, D.L. Greiner, et al., T cell-
speciﬁc siRNA delivery suppresses HIV-1 infection in humanized mice, Cell.
134 (2008) 577e586.
[16] Maria Valentina Pasquetto, Luca Vecchia, Daniele Covini, Rita Digilio, C. Scotti,
Targeted drug delivery using immunoconjugates: principles and applications,
J. Immunother. 34 (2011) 611e628.
[17] P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman,
J.B. Rothbard, The design, synthesis, and evaluation of molecules that enable
or enhance cellular uptake: peptoid molecular transporters, Proc. Natl. Acad.
Sci. U. S. A. 97 (2000) 13003e13008.
[18] R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014, CA Cancer J. Clin. 64
(2014) 9e29.
[19] T. Li, Y.H. Ling, I.D. Goldman, R. Perez-Soler, Schedule-dependent cytotoxic
synergism of pemetrexed and erlotinib in human non-small cell lung cancer
cells, Clin. Cancer Res. 13 (2007) 3413e3422.
[20] R. Sordella, D.W. Bell, D.A. Haber, J. Settleman, Geﬁtinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways, Science 305
(2004) 1163e1167.
[21] P.C. Ma, R. Jagadeeswaran, S. Jagadeesh, M.S. Tretiakova, V. Nallasura, E.A. Fox,
et al., Functional expression and mutations of c-Met and its therapeutic in-
hibition with SU11274 and small interfering RNA in non-small cell lung
cancer, Cancer Res. 65 (2005) 1479e1488.
[22] L.V. Sequist, J.C. Yang, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, et al., Phase
III study of afatinib or cisplatin plus pemetrexed in patients with metastatic
lung adenocarcinoma with EGFR mutations, J. Clin. Oncol. Off. J. Am. Soc. Clin.
Oncol. 31 (2013) 3327e3334.
[23] P.A. Janne, J.C. Yang, D.W. Kim, D. Planchard, Y. Ohe, S.S. Ramalingam, et al.,
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N. Engl. J.
Med. 372 (2015) 1689e1699.
[24] C.A. Eberlein, D. Stetson, A.A. Markovets, K.J. Al-Kadhimi, Z. Lai, P.R. Fisher, et
al., Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is asso-
ciated with increased dependence on RAS signaling in preclinical models,
Cancer Res. 75 (2015) 2489e2500.
[25] P.J. Roberts, T.E. Stinchcombe, KRAS mutation: should we test for it, and doesit matter? J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31 (2013) 1112e1121.
[26] K. Suda, K. Tomizawa, T. Mitsudomi, Biological and clinical signiﬁcance of
KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR
mutation, Cancer Metastasis Rev. 29 (2010) 49e60.
[27] J. Downward, Targeting RAS signalling pathways in cancer therapy, Nat. Rev.
Cancer 3 (2003) 11e22.
[28] J.A. Engelman, P.A. Janne, Mechanisms of acquired resistance to epidermal
growth factor receptor tyrosine kinase inhibitors in non-small cell lung can-
cer, Clin. Cancer Res. 14 (2008) 2895e2899.
[29] G. Scagliotti, J. von Pawel, S. Novello, R. Ramlau, A. Favaretto, F. Barlesi, et al.,
Phase III multinational, randomized, double-blind, placebo-controlled study
of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously
treated patients with locally advanced or metastatic nonsquamous non-
esmall-cell lung cancer, J. Clin. Oncol. 33 (2015) 2667e2674.
[30] G. Chen, P. Kronenberger, E. Teugels, I.A. Umelo, J. De Greve, Targeting the
epidermal growth factor receptor in non-small cell lung cancer cells: the ef-
fect of combining RNA interference with tyrosine kinase inhibitors or cetux-
imab, BMC Med. 10 (2012) 28.
[31] C. Stahlhut, F.J. Slack, Combinatorial Action of MicroRNAs let-7 and miR-34
effectively synergizes with erlotinib to suppress non-small cell lung cancer
cell proliferation, Cell Cycle 14 (2015) 2171e2180.
[32] K. Jiang, J. Li, J. Yin, Q. Ma, B. Yan, X. Zhang, et al., Targeted delivery of CXCR4-
siRNA by scFv for HER2 breast cancer therapy, Biomaterials 59 (2015) 77e87.
[33] U. Bode, M. Massimino, F. Bach, M. Zimmermann, E. Khuhlaeva, M. Westphal,
et al., Nimotuzumab treatment of malignant gliomas, Expert Opin. Biol. Ther.
12 (2012) 1649e1659.
[34] M. Sundvall, A. Karrila, J. Nordberg, R. Grenman, K. Elenius, EGFR targeting
drugs in the treatment of head and neck squamous cell carcinoma, Expert
Opin. Emerg. Drugs 15 (2010) 185e201.
[35] C. Gridelli, P. Maione, M.L. Ferrara, A. Rossi, Cetuximab and other anti-
epidermal growth factor receptor monoclonal antibodies in the treatment
of non-small cell lung cancer, Oncologist 14 (2009) 601e611.
[36] A. Fasih, H. Fonge, Z. Cai, J.V. Leyton, I. Tikhomirov, S.J. Done, et al., 111In-Bn-
DTPA-nimotuzumab with/without modiﬁcation with nuclear translocation
sequence (NLS) peptides: an Auger electron-emitting radio-
immunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-
resistant breast cancer, Breast Cancer Res. Treat. 135 (2012) 189e200.
[37] P.P. Luk, P. Galettis, M. Links, ERK phosphorylation predicts synergism be-
tween gemcitabine and the epidermal growth factor receptor inhibitor
AG1478, Lung Cancer 73 (2011) 274e282.
[38] N. Sunaga, D.S. Shames, L. Girard, M. Peyton, J.E. Larsen, H. Imai, et al.,
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses
tumor growth and sensitizes tumor cells to targeted therapy, Mol. Cancer
Ther. 10 (2011) 336e346.
[39] A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, et al.,
A gene expression signature associated with “K-Ras addiction” reveals regu-
lators of EMT and tumor cell survival, Cancer Cell 15 (2009) 489e500.
[40] B. Lutterbach, Q. Zeng, L.J. Davis, H. Hatch, G. Hang, N.E. Kohl, et al., Lung
cancer cell lines harboring MET gene ampliﬁcation are dependent on Met for
growth and survival, Cancer Res. 67 (2007) 2081e2088.
[41] W. Wang, Q. Li, S. Takeuchi, T. Yamada, H. Koizumi, T. Nakamura, et al., Met
kinase inhibitor E7050 reverses three different mechanisms of hepatocyte
growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant
lung cancer, Clin. Cancer Res. 18 (2012) 1663e1671.
[42] E. Song, P. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, et al.,
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface
receptors, Nat. Biotechnol. 23 (2005) 709e717.
[43] C.L. Arteaga, Overview of epidermal growth factor receptor biology and its
role as a therapeutic target in human neoplasia, Semin. Oncol. 29 (2002) 3e9.
